| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4581743
Max Phase: Preclinical
Molecular Formula: C20H17ClN2O5
Molecular Weight: 400.82
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: Cc1noc(C)c1-c1ccc(C(=O)O)c(NC(=O)COc2ccccc2Cl)c1
Standard InChI: InChI=1S/C20H17ClN2O5/c1-11-19(12(2)28-23-11)13-7-8-14(20(25)26)16(9-13)22-18(24)10-27-17-6-4-3-5-15(17)21/h3-9H,10H2,1-2H3,(H,22,24)(H,25,26)
Standard InChI Key: LSTPBCUWOCHEMX-UHFFFAOYSA-N
Associated Targets(Human)
Transient receptor potential cation channel subfamily M member 4 31 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 400.82 | Molecular Weight (Monoisotopic): 400.0826 | AlogP: 4.33 | #Rotatable Bonds: 6 |
| Polar Surface Area: 101.66 | Molecular Species: ACID | HBA: 5 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 3.45 | CX Basic pKa: 1.40 | CX LogP: 3.98 | CX LogD: 0.59 |
| Aromatic Rings: 3 | Heavy Atoms: 28 | QED Weighted: 0.64 | Np Likeness Score: -1.59 |
References
| 1. Delalande C, Awale M, Rubin M, Probst D, Ozhathil LC, Gertsch J, Abriel H, Reymond JL.. (2019) Optimizing TRPM4 inhibitors in the MHFP6 chemical space., 166 [PMID:30708257] [10.1016/j.ejmech.2019.01.048] |
Source
Source(1):